Blinatumomab [BLI1]
The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in ADULT patients
- An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
- The patient has relapsed or refractory Philadelphia negative acute lymphoblastic leukaemia (ALL).
- The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage therapy or inotuzumab ozagamicin
- The patient is an adult* *note there is a separate Blueteq form to be used for blinatumomab in this indication in children.
- Blinatumomab should only be requested by and administered in either bone marrow transplant centres or in major haematological centres that regularly treat patients with relapsed ALL and who have close and regular ALL multi- disciplinary team meetings and links with bone marrow transplant centres.
- The patient has an ECOG performance status of 0 - 2.
- A maximum of 5 cycles of treatment with blinatumomab will be administered.
- Blinatumomab will be used as monotherapy
- No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process
- Blinatumomab should otherwise be used as set out in its Summary of Product Characteristics (SPC).
[NHS funded]{.badge .rounded-pill .bg-success} From: 26 September 2017
Additional information
Current Form Version
Important
This is an older version of the form. To view the most up to date form follow this link